[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

148 Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Program: Oral and Poster Abstracts
Type: Oral
Session: 721. Clinical Allogeneic Transplantation - Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Outcomes
Sunday, December 11, 2011: 4:30 PM
Douglas Pavilion D (Manchester Grand Hyatt San Diego)

Nicolaus Kröger1*, Tatjana Zabelina, MD2*, Francis Ayuk, MD2*, Christine Wolschke, MD3*, Haefaa Alchalby4*, Anita Badbaran5*, Djordje Atanackovic, M.D.6*, Georgia Schilling, MD7*, Orhan Sezer, MD, PhD8, Ulrike Bacher, MD2*, Thomas Stübig, MD3*, Boris Fehse, Ph.D.9* and Axel R. Zander, MD1

1Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2Department for Stem Cell Transplantation, University of Hamburg, Hamburg, Germany
3Clinic for Stem Cell Transplantation, University Cancer Center Hamburg-Eppendorf, Hamburg, Germany
4Department of Stem Cell Transplantation, University Cancer Center Hamburg-Eppendorf, Hamburg, Germany
5Center of Oncology - Bone Marrow Transplantation Unit, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
6Hubertus Wald University Cancer Center, Department of Oncology and Hematology with sections Pneumonology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Tumorzentrum-University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
8Dep. Hematology, Oncology and Stem Cell Transplantation, Hamburg University Medical Center, Hamburg, Germany
9Research Department Cell and Gene Therapy, Clinic for Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf

Multiple Myeloma (MM) is considered to be an incurable disease, but in some patient long-term survival can be achieved after high dose chemotherapy followed by autologous or allogeneic stem cell transplantation. Those patients, who achieved molecular remission, have a high probability of long-term disease-freedom and of cure. More recently  the introduction of dose-reduced conditioning and the use of auto-allo tandem approach has broaden the use of allogeneic stem cell transplantation in MM, but the results of prospective trials are controversial. We here investigated within a prospective protocol the incidence and impact of molecular remission on long-term outcome obtained after auto-allo tandem approach in MM. (study registration NCT 00781170).

From 4/2000 to 10/2008, 73 patients with a median age of 50 years (r 29-64) and advanced stage II/III MM were included. The conditioning regimen for autologous transplantation consisted of melphalan 200 mg/m2 given divided over 2 days. After an interval of 2-3 months, the patients received a dose-reduced conditioning consisting of melphalan 140 mg/m2, fludarabine 180 mg/m2 and ATG Fresenius® (Fresenius, Bad Homburg, Germany) at a dose of 10 mg/kg for related and 20 mg/kg for unrelated donors on day -3, -2, and -1 followed by allogeneic stem cell transplantation.

Remission was defined according to modified EBMT criteria. In 46 patients with CR or nCR minimal residual disease could be monitored by myeloma-specific primers (allele specific oligonucleotides, ASO) targeting IgH gene rearrangements (n=20) or by highly sensitive plasma cell chimerism using real-time PCR after magnet-activated cell sorting of CD138+ cells (n=26). The sensitivity of plasma cell chimerism was 10-4 using real-time PCR and donor/patient specific polymorphisms and 10-5 in case of Y-PCR. Sensitivity for nested PCR with myeloma-specific primers was 10-5. In 5 patients only 1 MRD measurement was available and those patients were excluded from MRD sub-analysis. Molecular complete remission was defined as by least two negative PCR results with ASO primers or achievement of at least two times ≥99.9 % donor chimerism of plasma cells by real-time PCR from bone marrow samples. Sustained MRD negativity was defined by at least 4 negative molecular results either by ASO primer or plasma-cell chimerism. Mixed MRD was defined by negative molecular markers for at least two times, but intermittent positivity was defined by myeloma-specific primers or plasma cell chimerism. 

Overall 44 patients (60 %) achieved a CR according to EBMT criteria with negative immunofixation. 8 % achieved a VGPR and 18 % a partial remission. 3 % had progressive disease and 11 % were not evaluable for determination of remission. Molecular remission was observed in 30 patients, in 15 patients the molecular markers were sustained negative while in 15 patients molecular markers were only intermittent negative, resulting in an overall complete molecular remission rate of 46 % and a stable sustained complete molecular remission rate of 23 %.

After a median follow-up at 7 years the 5 year progressive-free survival was 29 % (95% CI: 17-41%). Patients without del(13q14) had a significantly better PFS than those with del(13q14) (5 y: 56% vs. 17%, p=0.02). Patients who achieved CR after transplantation had improved PFS in comparison to non-CR patients (5 y: 41% vs. 28%, p=0.008). Patients with sustained negative molecular remission had a 5 year PFS of 85 % vs. 31 % for mixed molecular remission (p= 0.003).

The 5 year overall survival was 52 % (95% CI: 40-64%). Patients without del(13q14) had significantly improved 5 year survival (75% vs. 40%. p=0.02). Patients who achieved a sustained molecular remission had a 5 year OS of 91 % while those with mixed molecular remission resulted in a 5 year OS of 87 % (p=0.06).

The study underlines the importance of the depth of remission and shows that achieving molecular remission as determined by myeloma-specific IgH gene rearrangements and plasma cell chimerism is associated with long-term freedom from disease and potential cure of MM in an auto-/allo SCT approach.



MRD sustained neg,MRD mixed,MRD pos,p<0.001 


Disclosures: No relevant conflicts of interest to declare.

*signifies non-member of ASH